ALLMedicine™ Exfoliative Dermatitis Center

Jun 22nd, 2021 - Practice Essentials Exfoliative dermatitis is characterized by generalized erythema with scaling or desquamation affecting at least 90% of the body surface area. Systemic derangements may occur with exfoliative dermatitis, including peripheral ede...

Jun 17th, 2021 - Canine leishmaniosis (CanL) is a zoonotic disease caused by Leishmania infantum. Although usually transmitted by phlebotomine sand flies, infection by vertical transmission and by blood transfusion have also been reported. We describe the very ear...

Apr 6th, 2021 - Erythroderma (exfoliative dermatitis) is associated with important metabolic changes that include an enhancement in energy expenditure. The key components to total energy expenditure (TEE) include basal metabolic rate (~68% of TEE), physical activ...

Feb 28th, 2021 - Erythroderma (exfoliative dermatitis), first described by Von Hebra in 1868, manifests as a cutaneous inflammatory state, with associated skin barrier and metabolic dysfunctions. The annual incidence of erythroderma is estimated to be 1-2 per 100 ...

Feb 7th, 2021 - Gouty arthritis (GA) is a chronic disease caused by monosodium urate crystal deposition. Repeated attacks of arthritis may lead to the deposition of urate to form gout stone, resulting in joint deformity and joint damage. Although GA is not fatal,...

Aug 22nd, 2012 - Background : The most frequent cutaneous T-cell lymphomas (CTCL) are mycosis fungoid and Sezary syndrome. Both are due to the proliferation of a CD4+ T-cell clone in the skin, associated with a blood involvement in Sezary syndrome. Mycosis fungoid...

Nov 13th, 2020 - Bruno Strigini, CEO The European Commission has approved midostaurin (Rydapt) for adults with newly diagnosed FLT3-positive acute myeloid leukemia (AML) and advanced systemic mastocytosis (SM), including aggressive systemic mastocytosis (SM), SM ...

Sep 14th, 2017 - The Food and Drug Administration has approved a biosimilar to bevacizumab (Avastin) for the treatment of certain colorectal, lung, brain, kidney, and cervical cancers. Bevacizumab-awwb is the first biosimilar approved in the United States for the.

Sep 14th, 2017 - The US Food and Drug Administration (FDA) has approved the first biosimilar for use in oncology ― the product is Mvasi (bevacizumab-awwb), from Amgen. It is equivalent to the reference product, Avastin (Genetech/Roche), which was first approved in...

Oct 28th, 2005 - CAMBRIDGE, Mass., Oct. 28 - Biogen Idec and the FDA issued a drug safety alert today advising physicians that the Zevalin therapeutic regimen has been associated with severe cutaneous or mucocutaneous reactions, some of which have been fatal. "Sim...

Abstract and Introduction Abstract The life-threatening DRESS (drug rash with eosinophilia and systemic symptoms) syndrome is characterized by the presence of at least three of the following findings: fever, exanthema, eosinophilia, atypical circu...